Resveratrol-fortification of red wine does not provide greater inhibition of human lung cancer cell survival compared to non-fortified wine. by Moore, Jessy et al.
Lung cancer is the leading cause of cancer-related 
deaths, and individuals with this disease often develop 
resistance to conventional cytotoxic therapies. Red 
wine and its polyphenolic component resveratrol, have 
been shown to have anticancer effects. Wines fortified 
with resveratrol have been marketed as having addi-
tional health benefits because of their increased poly-
phenolic content, however no studies exist examining 
this claim. The aim of the present study was to explore 
the effects of resveratrol-fortified red wine on lung 
cancer cell survival. Human NSCLC A549 cells were 
treated with varying concentrations of red wine with or 
without trans-resveratrol fortification. Cell survival 
was assessed using clonogenic assays and im-
munoblotting was used to explore the effects on Akt 
and ERK signaling molecules. Red wine significantly 
inhibited cell survival at concentrations as low as 
0.02%, and significantly reduced phosphorylation of 
both Akt and ERK. No significant differences were 
seen between regular and resveratrol-fortified red 
wine. These data suggest that red wine may have con-
siderable cancer preventive potential, however it does 
not support the use of resveratrol-fortified wine for 
additional health benefits. 
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Introduction 
 
As a single entity, cancer is the largest cause 
of mortality globally. Lung cancer accounts for the 
most cancer related deaths (Stewart & Wild 2014) with 
non-small cell lung cancer (NSCLC) accounting for 
the majority (85%) of lung cancer cases (Jones et al. 
2015). Unfortunately, the outcome of NSCLC is very 
poor with fewer than 20% of patients reaching a 5 year 
survival and this statistic exists despite the use of ag-
gressive chemotherapy and/or radiation treatment 
(Jones et al. 2015). NSCLC often develops resistance 
to conventional cancer treatments (Rothschild 2015, 
Thomas et al. 2015), strongly indicating an urgent 
need to identify new effective strategies for its preven-
tion and treatment. 
 Cancer in general is characterized by enhanced 
growth factor signaling leading to increased prolifera-
tion and reduced programmed cell death (apoptosis) 
(Hanahan & Weinberg 2011). The phosphatidylinosi-
tol 3-kinase (PI3K)-Akt signaling cascade is activated 
downstream of growth factor receptors, following their 
stimulation upon ligand binding, leading to cell sur-
vival (inhibition of apoptosis) and enhanced prolifera-
tion (Manning & Cantley 2007). Indeed when Akt is 
activated apoptosis is inhibited due to phosphorylation 
and degradation of the pro-apoptotic protein Bad 
(Manning & Cantley 2007) and phosphorylation of 
murine double minute 2 (MDM2) homologue, which 
then translocates into the nucleus and inhibits p53 lev-
els (Mayo & Donner 2001). On the other hand, acti-
vated Akt leads to downstream activation of the mam-
malian target of rapamycin (mTOR) and p70 S6 
kinase, resulting in stimulation of protein synthesis, 
growth and proliferation (Manning & Cantley 2007). 
 Many studies have shown that Akt levels and 
its activation are increased in many cancer cells and 
human tumors (Brognard et al. 2001, Liu et al.2009), 
and when Akt signaling is inhibited cancer cell prolif-
eration is reduced and apoptosis is increased (Brognard 
et al. 2001, Ermoian et al. 2002, Pérez-Tenorio & Stål 
2002). Akt is a proto-oncogene and its activation is 
also implicated in the induction of resistance to chemo
- and radio-therapy (Brognard et al. 2001, Liu et al. 
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2007). Based on this evidence, the scientific commu-
nity has focused on finding chemicals that will target/
inhibit Akt as a strategy to prevent and treat cancer 
(Ciuffreda et al. 2014). 
 The Ras- mitogen-activated protein kinase 
(MAPK) signaling cascade is also activated down-
stream of growth factor receptor stimulation, leading 
to increased proliferation. The extracellular signal-
regulated kinase (ERK), a member of the MAPK fam-
ily, is activated in cancer leading to enhanced cell pro-
liferation and survival (Ciuffreda et al. 2014, Roberts 
& Der 2007). Mutations to the Ras and Raf oncogenes, 
which are located upstream in this signaling cascade 
and thus control activation of ERK, are frequent in 
human cancers and notably in lung cancers (Davies et 
al., 2002), highlighting the importance of targeting this 
pathway using novel anticancer agents (Gentry et al. 
2013). 
 Compounds of plant origin and food compo-
nents have attracted scientific attention for use as 
agents for cancer prevention and treatment. Recent 
studies indicate that wine may have anticancer proper-
ties (Barron et al. 2014, Elattar & Virji 1998, Wallen-
borg et al. 2009). Red wine inhibited the proliferation 
of human prostate cancer cells (Kampa et al. 2000) and 
human oral squamous carcinoma (SCC-25) cells 
(Elattar & Virji 1998) while it increased lung, colon 
and cervical cancer cell death (Wallenborg et al. 
2009).  In a recent study by our group we found a sig-
nificant inhibition of human lung cancer cell prolifera-
tion and survival by wine (Barron et al. 2014). 
 The polyphenol resveratrol is found at a rela-
tively high concentration in red wine (1-5 mg/L) and 
has been proposed to be responsible for the reduced 
incidence of cardiovascular disease associated with 
moderate wine consumption (German & Walzem 
2000, Zordoky et al. 2015). Similarly, it is thought that 
the potential anticancer properties of wine may be at-
tributable to its resveratrol content, and both in vitro 
and in vivo studies with resveratrol support such think-
ing (Aluyen et al. 2012, Jang et al. 1997, Yang et al. 
2014). Resveratrol has been shown to inhibit growth of 
multiple myeloma (Sun et al. 2006), uterine (Sexton et 
al. 2006), pancreatic (Golkar et al. 2007) and lung 
(Kubota et al. 2002) cancer cells. In addition, in ani-
mals in vivo, resveratrol inhibited diethylnitrosamine 
(DENA)-induced liver cancer (Bishayee & Dhir 2009), 
colorectal cancer  (Tessitore et al. 2000) and enhanced 
radio-sensitivity of prostate cancer (Rashid et al. 
2011). Resveratrol is extracted from grape skins into 
red wine during vinification, where it is found in four 
forms: trans- and cis-aglycone, and trans- and cis-
glycoside. The relative concentrations of these forms 
are mediated by isomerisation and hydrolytic reac-
tions, although the trans-form of the aglycone is more 
abundant than the cis (Mattivi et al. 1995). 
 The evidence of the anticancer properties of 
resveratrol has prompted the production of resveratrol-
fortified wines, which are being marketed as having 
enhanced health benefits (Norrie 2009), and is consis-
tent with the recent increase in functional foods forti-
fied with phenolic compounds (Gaudette & Pickering 
2013). However the biological effects and whether an 
added benefit is provided by such wine is not known, 
and there are no studies examining the effects of res-
veratrol-fortified wine on cancer. In the present study 
we examined the effects of red wine with or without 
added trans-resveratrol (at two concentrations) on lung 
cancer cell survival and on the Akt and ERK signaling 
cascades. 
 
Materials and Methods 
 
Materials 
Human A549 NSCLC cells and MRC5 normal lung 
fibroblasts were purchased from American Type Cul-
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Table 1. Basic physicochemical composition and phenolic content of Cabernet Sauvignon wines. Data represent mean values of 
duplicate measurements from duplicate bottles ± standard deviations. Means sharing the same letter do not differ significantly 
(Fisher’s Protected LSD 0.05).   Modified from Gaudette & Pickering (2011). 
 
  
trans- RSV 
(mg/L) 
  
cis-RSV 
(mg/L) 
  
Total  
Phenolics  
(A280 nm
-4) 
  
Free SO2 
(mg/L) 
  
Total Red 
Pigments (A520 
nm/AHCl520 
nm x 100) 
Titratable 
Acidity (g/L) 
  
pH 
  
Antioxidant 
Capacity 
(Trolox™  
equivalent) 
– RSV <  0.49 < 0.13 22.2 a ± 0.38 8.40 a ± 1.53 10.8 a ± 0.13 6.06 a ± 0.20 3.09 a ± 0.02 30.33 a ± 0.14 
+20 mg/L RSV 12.9 a ± 0.16 < 0.13 24.7 b ± 1.47 6.40 b ± 0.00 11.6 b ± 0.59 5.98 a ± 0.17 3.06 a ± 0.00 32.9 ab ± 1.36 
+200 mg/L RSV 146.0 b ± 1.88 0.33 ± 0.06 33.6 c ± 0.65 6.80 b ± 0.80 11.1 c ± 0.15 5.49 b ± 0.46 3.08 a ± 0.01 35.2 b ± 0.34 
ture Collection (ATCC). Cell culture (RPMI & 
DMEM) media, fetal bovine serum (FBS), trypsin, and 
antibiotic were purchased from GIBCO (Burlington, 
ON, Canada). Crystal violet dye and 10% formalin 
were purchased form Sigma Aldrich (Oakville, ON, 
Canada). Total and phospho-specific Akt and ERK 
antibodies and secondary antibodies were purchased 
from New England Biolabs (Mississauga, ON, Can-
ada). Primary β-actin antibody was purchased from 
Santa Cruz Biotechnology (Dallas, TX, U.S.A). Red 
wine (Cabernet Sauvignon) with or without added res-
veratrol was prepared at the Cool Climate Oenology 
and Viticulture Institute (CCOVI), Brock University. 
trans-Resveratrol (99% pure food grade; Chromadex, 
Irvine, California, USA) was added to wine at 20mg/L 
or 200 mg/L prior to bottling as previously described 
(Gaudette & Pickering, 2011). The basic physico-
chemical composition and phenolic content of the 
wines were measured as previously described 
(Gaudette & Pickering 2011).   
 
Cell Culture and Treatment 
A549 cells were grown in RPMI media and MRC5 
cells were grown in DMEM media, each supplemented 
with 10% (v/v) FBS and 1% (v/v) antibiotic-
antimycotic solution (100 U/ml penicillin, 100 µg/ml 
streptomycin, and 250 ng/ml amphotericin B) in a hu-
midified atmosphere of 5% CO2- 95% air at 37°C. 
Cells were seeded in 6 well plates and treated with the 
indicated concentrations of red wine with or without 
added resveratrol for the indicated times as stated in 
each figure. 
 
Clonogenic Assay 
Clonogenic assays were performed as described previ-
ously (Barron et al. 2014). Cells (800-1000) were 
counted using a haemocytometer, seeded in triplicate 
and allowed to adhere overnight. The next day cells 
were treated with the indicated concentrations of red 
wine with or without added resveratrol (mixed in 10% 
FBS containing media), followed by incubation for 7 
days. On day 7 cells were fixed and stained with 
0.05% (w/v) methylene blue and colonies (> 50 cells) 
were counted. Results are expressed as the surviving 
fraction compared to untreated control. 
 
Crystal Violet Assay 
Cells (800-1000) were counted using a haemocytom-
eter, seeded in triplicate in 96 well plates and allowed 
to adhere overnight. The next day cells were treated 
with the indicated concentrations of red wine with or 
without added resveratrol (mixed in 10% FBS contain-
ing media) and incubated for 72 hours. Following 
treatment cells were fixed with 10% formalin, stained 
with crystal violet, rinsed with tap water and allowed 
to dry overnight. The next day, adhered crystal violet 
stain was solubilized and absorbance was measured at 
570nm using the KC4 plate reader. Results are ex-
pressed as percent of untreated control. 
 
Immunoblotting 
A549 or MRC5 cells were seeded in 6-well plates at a 
high density and allowed to adhere overnight. The fol-
lowing day the media in the plates was replaced with 
0% FBS containing media and cells were serum de-
prived for 24h. Cells were then treated with the indi-
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Figure 1. Red wine inhibits cell survival in A549 NSCLC 
cells. Cells were incubated without or with the indicated 
concentrations of Cabernet Sauvignon wine for 7 days fol-
lowed by fixing and staining with 0.05% methylene blue. 
Colonies containing more than 50 cells were counted. Re-
sults are expressed as the surviving fraction ± SEM com-
pared to untreated control of 3-4 independent experiments. 
*p<0.05, ***p<0.001 vs. control 
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Figure 2. Red wine inhibits cell proliferation in A549 
NSCLC cells. Cells were incubated without or with the indi-
cated concentrations of Cabernet Sauvignon wine for 72 
hours, fixed and stained with crystal violet dye. Adhered dye 
was solubilized and absorbance was read at 570nm. Results 
are expressed as the % cell proliferation ± SEM compared to 
untreated control of 3 independent experiments. ***p<0.001 
vs. control 
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cated concentrations of red wine with or without added 
resveratrol for another 24h (in 0% FBS containing me-
dia). After treatment, cell lysates were prepared fol-
lowed by separation of 20 μg of protein sample by so-
dium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE). Protein was then transferred to poly-
vinylidene fluoride (PVDF) membrane and blocked 
with 5% milk. Membranes were incubated with total- 
or phospho- specific Akt, ERK or β-actin antibodies 
overnight. The next day, secondary antibody was ap-
plied to the membrane for 1h and bands were detected 
using Biorad Clarity ECL substrate.  Densitometric 
analysis was performed using Image J software. Re-
sults are expressed in arbitrary densitometric units as 
the mean ± SEM of control.  
 
Statistical Analysis  
The results are the mean ± SEM of the indicated num-
ber of independent experiments. Analysis of variance 
(ANOVA) with Tukey post-hoc testing was used. Sta-
tistical significance was assumed at p<0.05. GraphPad 
Prism 6 Software was used for statistical analysis. 
 
Results 
 
The physicochemical composition of the red wines 
used is shown in Table 1. We aimed to have low and 
high levels of resveratrol fortification, thus 20mg/L or 
200 mg/L of resveratrol was added, with the latter 
value reflecting the approximate upper limit of solubil-
ity. As reported by Gaudette & Pickering (2011), a 
small initial decrease in content occurred after bottling 
-possibly due to the known propensity of polyphenols 
to self-associate and complex with other wine constitu-
ents - yielding final and stable concentrations of 12.9 
mg/L and 146 mg/L, respectively. For the rest of the 
paper unfortified wine is also referred to as – RSV, 
while wine with low and high levels of resveratrol for-
tification are referred to as + RSV and ++ RSV respec-
tively. 
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Table 2. Calculated final trans-resveratrol concentration in the media containing different wine concentrations (%) 
 Media [Wine]%:  0.02  0.2  0.5  1   2 
-RSV (2.14µM) 
+RSV (56.5µM) 
0.429nM 
11.3nM 
4.29nM 
113nM 
 10.73nM 
282.5nM 
 21.46nM 
565nM 
 42.92nM 
1.13µM 
++RSV (639.68µM) 128nM 1.28µM 3.20µM 6.40µM 12.79µM 
Figure 3. Effect of red wine on Akt signaling in A549 NSCLC cells. Whole cell lysates were prepared from A549 cells that 
were serum-deprived for 24h then treated without or with A) 1% or B) 0.02% wine for 24h. Cell lysates (20µg) were resolved 
by SDS-PAGE and immunoblotted with total- or phospho- specific antibodies against Akt. A representative immunoblot is 
shown. The densitometry of the bands expressed in arbitrary units was measured using Image J software. Protein levels are 
expressed as a percentage of the control. Results represent mean ± SEM of 3 independent experiments. ***p<0.001 vs. control 
Effects of resveratrol-fortified wine on lung cancer 
cell survival and proliferation 
A549 lung cancer cells were exposed to media without 
or with different concentrations (0.02, 0.2, 0.5, 1, 2%) 
of red wine, and clonogenic cell survival was meas-
ured.  Exposure to red wine resulted in a dose-
dependent inhibition of clonogenic cell survival.  A 
significant inhibition was seen at 0.02% red wine (-
RSV: 53.8±3.8% of untreated control) (Figure 1). In-
terestingly, the same level of inhibition of clonogenic 
survival was seen with wine fortified with resveratrol 
(+RSV: 45.5±8.0%; ++RSV: 50±9.5% of untreated 
control) (Figure 1). Red wine at 2% abolished most of 
the ability of cells to create surviving colonies, and 
again no statistical differences were seen between for-
tified (+RSV: 3.0±1.7%; ++RSV: 0.3±0.3% of un-
treated control) and unfortified wine (-RSV: 2.8±1.6% 
of untreated control) (Figure 1). These data clearly in-
dicate that red wine induces a significant inhibition of 
lung cancer cell survival and this effect is not potenti-
ated by the addition of resveratrol into the wine. 
 To examine the effect of red wine on A549 
lung cancer cell proliferation, the crystal violet assay 
was used. Cells were exposed to media without or with 
different concentrations of wine (0.02, 0.05, 0.2, 0.5, 1, 
2%) and a dose-dependent inhibition of cell prolifera-
tion was seen (Figure 2). Red wine induced a signifi-
cant inhibition at 0.02% (-RSV: 76.1±1.5%, +RSV: 
77.7±1.2%; ++RSV: 78.8±1.2% of untreated control) 
without any differences observed with resveratrol forti-
fication.  At 5% fortified and unfortified red wine in-
hibited cell proliferation to the same extent (-RSV: 
33.2±1.2%; +RSV: 35.6±0.7%; ++RSV: 30.7±1.1% of 
untreated control). The IC50 of unfortified red wine 
was 2.95% and was not different than fortified wine. 
 Based on the concentration of resveratrol in 
the wines used and the molecular weight of resveratrol 
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Figure 4. Effect of red wine on ERK signaling in A549 NSCLC cells. Whole cell lysates were prepared from A549 cells that 
were serum-deprived for 24h then treated without or with A) 1% or B) 0.02% wine for 24h. Cell lysates (20µg) were resolved 
by SDS-PAGE and immunoblotted with total- or phospho- specific antibodies against ERK. A representative immunoblot is 
shown. The densitometry of the bands expressed in arbitrary units was measured using Image J software. Protein levels are 
expressed as a percentage of the control. Results represent mean ± SEM of 3 independent experiments. ***p<0.001 vs. control 
C
on
tr
ol
0.
02
%
0.
5%
1.
0%
2.
0%
5.
0%
 
0
50
100
- RSV
+ RSV
++ RSV
Red Wine Concentration (%)
%
 C
el
l 
P
ro
li
fe
ra
ti
o
n
(c
o
m
p
a
re
d
 t
o
 u
n
tr
ea
te
d
 c
o
n
tr
o
l)
Figure 5. Red wine does not inhibit cell proliferation in non
-cancerous MRC5 lung cells. MRC5 normal lung fibro-
blasts were incubated without or with the indicated concen-
trations of Cabernet Sauvignon wine for 72 hours, fixed and 
stained with crystal violet dye. Adhered dye was solubilized 
and absorbance was read at 570nm. Results are expressed as 
the % cell proliferation ± SEM compared to untreated con-
trol of 3 independent experiments. 
(228.24 g/mol), we calculated the final concentration 
of resveratrol in the media containing different wine 
concentrations (Table 2). These values are the calcu-
lated final concentrations of resveratrol the cells were 
exposed to. Although, as it can be seen from Table 2, 
the cells were exposed to significantly different res-
veratrol concentrations, the level of inhibition of 
clonogenic survival was not significantly different 
(Figure 1). For example, cells that were treated with 
0.02% fortified red wine were exposed to 11.3 nM 
or128 nM resveratrol but the inhibition of clonogenic 
survival was 45.5±8.1 and 50.0±9.5% of control re-
spectively, and not different than the inhibition seen 
with unfortified wine exposed to only 0.429 nM res-
veratrol (-RSV: 53.8±3.8% of untreated control). The 
same was observed for the inhibition of proliferation. 
 
Effects of resveratrol-fortified wine on Akt phos-
phorylation/activation. 
As reported by our group previously (Barron et al. 
2014), control/untreated A549 cells have high levels of 
Akt phosphorylation which correlate with  the activa-
tion of this enzyme (Manning & Cantley 2007). Treat-
ment of the cells with 1% red wine significantly inhib-
ited Akt phosphorylation (-RSV: 36.9±2.0% of con-
trol) (Figure 3A) and low or high resveratrol fortifica-
tion of red wine did not result in any further reduction 
in Akt phosphorylation (+RSV: 32.2±2.4%; ++RSV: 
32.1±3.3% of control). Treatment of the cells with a 
much lower concentration (0.02%) of wine showed a 
tendency to decrease Akt phosphorylation, but it was 
not statistically different than control even in the 
groups treated with the fortified wine (-RSV: 
74.6±12.3%; +RSV: 74.4±13.7%; ++RSV: 
73.4±13.2% of control) (Figure 3B). Total Akt levels 
were not significantly changed by any treatment 
(Figure 3A, 3B). 
 
Effects of resveratrol-fortified wine on ERK phos-
phorylation/activation. 
Untreated A549 cells showed high levels of basal ERK 
phosphorylation, and red wine (1%) with or without 
resveratrol fortification reduced basal ERK phosphory-
lation significantly (-RSV: 57.4±7.4%; +RSV: 
56.6±5.6%; ++RSV: 56.2±6.0% of control) without 
affecting the total levels of this enzyme (Figure 4A). 
Similarly to Akt data, treatment of the cells with red 
wine fortified with resveratrol did not result in a 
greater response compared to the response seen with 
wine without resveratrol fortification. Treatment of the 
cells with a lower concentration of wine (0.02%) did 
not result in significant inhibition of ERK phosphory-
lation even in the groups treated with fortified wine (-
RSV: 82.9±8.9%; +RSV: 82.5±6.8%; ++RSV: 
80.4±8.1% of control) (Figure 4B). Total ERK levels 
were not significantly changed by any treatment 
(Figure 4A, 4B). 
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Figure 6. Effect of red wine on Akt and ERK signaling in non-cancerous MRC5 lung cells. Whole cell lysates were prepared 
from MRC5 cells that were serum-deprived for 24h then treated with 1% wine for 24h. Cell lysates (20µg) were resolved by 
SDS-PAGE and immunoblotted with total- or phospho- specific antibodies against A) Akt or B) ERK. Insulin stimulated 
(100nM for 15min) L6 muscle cells were used as a positive control. A representative immunoblot is shown. The densitometry 
of the bands expressed in arbitrary units was measured using Image J software. Protein levels are expressed as a percentage of 
the control. Results represent mean ± SEM of 3 independent experiments.  ***p<0.001 vs. control 
Resveratrol-fortified wines do not effect cell prolif-
eration in non-cancerous lung cells 
To explore whether the anti-proliferative effects of red 
wine were specific to cancer cells, the normal lung 
fibroblast cell line MRC5 was used.  Exposure of 
MRC5 cells to various concentrations (0.02, 0.5, 1, 2, 
5%) of unfortified and fortified red wine did not result 
in significant inhibition of cell proliferation at any con-
centration used. Cell proliferation was not significantly 
inhibited even at 5% red wine (-RSV: 93.9±6.5%; 
+RSV: 90.0±2.9%; ++RSV: 89.7±5.6% of control) 
(Figure 5). 
 
Resveratrol-fortified wines do not effect Akt or 
ERK signaling in non-cancerous lung cells 
We examined phosphorylated and total Akt and ERK 
levels in MRC5 normal lung fibroblasts. Unlike can-
cerous A549 lung cells, non-cancerous MRC5 lung 
cells have low basal phosphorylated ERK and Akt lev-
els. Akt phosphorylation was almost undetected. We 
used a sample of insulin treated L6 muscle cells as a 
positive control. Akt phosphorylation was clearly seen 
in these cells indicating that lack of the detection in 
MRC-5 cells was not due to a technical problem. Both 
fortified and unfortified red wines (1%) had no effect 
on total or phosphorylated levels of Akt or ERK 
(Figure 6A and 6B respectively). Similarly, no effect 
was seen using 0.02% wine (data not shown). 
 
Discussion 
 
Lung cancer and specifically NSCLC is presented in 
both smokers and non-smokers with high frequency, 
and is associated with poor prognosis. In addition, 
NSCLC develops resistance to radiation and chemo-
therapy and therefore finding ways to prevent and treat 
this disease is of major importance. 
 Wine consumption in moderation has been 
linked to reduced cardiovascular disease, and limited 
in vitro (Barron et al. 2014, Elattar & Virji 1998, 
Wallenborg et al. 2009) and in vivo (Martínez et al. 
2005) studies suggest anticancer properties of wine. 
Red wine contains the polyphenol resveratrol which 
has been shown to inhibit cancer cell proliferation and 
survival by affecting various signaling cascades in-
volved in these processes (Aluyen et al. 2012, Kubota 
et al. 2002, Tessitore et al. 2000, Yang et al. 2014). 
Based on this evidence, wine fortified with resveratrol 
has been produced and is marketed as having addi-
tional health benefits compared to wine without any 
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Figure 7. Proposed mechanism for anti-cancer activity of  red wine in A549 lung cancer cells. 
fortification. However, no studies examining the ef-
fects of fortified wine currently exist. 
 In the present study, we found a significant 
dose-dependent inhibition of cancer cell proliferation 
and survival by the Cabernet Sauvignon red wine. 
Wine concentrations as low as 0.02% significantly in-
hibited cell proliferation and survival. The data from 
the present study are in agreement with our previous 
study, where the red wines Pinot Noir and Cabernet 
Franc at 0.02% significantly inhibited survival of 
A549 lung cancer cells (Barron et al. 2014). Surpris-
ingly, wine fortified with low or high resveratrol levels 
did not cause any further reduction in cancer cell pro-
liferation and survival compared to unfortified wine. 
These data clearly indicate that components naturally 
present in red wine are sufficient to significantly re-
duce cancer cell survival. Although the antioxidant 
capacity of the wines used varied by around 16% 
(Table 1), this did not have any significant effect on 
cell survival, suggesting that once a certain level of 
antioxidant activity is reached it is sufficient to reduce 
cancer cell survival. 
 A study by Elattar & Virji (1998) found that 
the wine polyphenols resveratrol (50µM) and quercetin 
(10, 25 or 50µM) alone induced significant inhibition 
of human oral squamous cell carcinoma (SCC-25) 
growth and DNA synthesis, however a combination of 
the two compounds resulted in an increased inhibitory 
effect. Similarly, combined grape polyphenols resvera-
trol, quercetin and catechin at concentrations of 0.5, 5 
or 20µM each significantly inhibited cell proliferation, 
induced apoptosis and enhanced cell cycle arrest in 
breast cancer cells and importantly, the combined 
treatment was more effective than treatment with any 
of the compounds alone (Castillo-Pichardo et al. 2009, 
Schlachterman et al. 2008). In vivo studies have also 
shown a greater inhibitory effect on tumor growth in 
nude mice xenografted with breast cancer cells using 
combined polyphenol treatment (resveratrol, quercetin, 
catechin; 5mg/Kg body weight each) (Castillo-
Pichardo et al. 2009, Schlachterman et al. 2008). 
These data support the hypothesis that red wine com-
ponents work synergistically to exert anticancer ef-
fects. This synergism may already be allowing wine to 
exert its maximal anticancer effects, and thus addition 
of resveratrol, or perhaps any other polyphenol, would 
not potentiate further these effects. 
 The inhibition of clonogenic cell survival by 
red wine clearly indicates that red wine has an anti-
oncogenic potential, and in an in vivo setting such inhi-
bition could lead to inability of a cancer cell to survive, 
form a colony and develop a tumor. Addition of red 
wine polyphenol extract in drinking water (100mg/Kg/
day) of BALB/c nude mice implanted with colon car-
cinoma cells and Wistar rats injected with the carcino-
gen azoxymethane resulted in decreased tumor growth, 
onset and development of preneoplastic lesions 
(Walter et al. 2010). Furthermore, tumor vasculariza-
tion, lung metastases and cell proliferation was de-
creased, and apoptosis was increased. These data 
clearly show that red wine polyphenols effectively re-
duce the development of colon carcinoma tumors in 
vivo and suggest anticancer and cancer preventive ef-
fects of wine that require further study. 
 The protein Akt has been established to play a 
major role in cell survival as its activation inhibits 
apoptosis and activates downstream the mTOR-
p70S6K signaling cascade leading to enhanced cell 
proliferation (Manning & Cantley 2007). The A549 
cells used in the present study express a mutant, acti-
vated Ras (K-Ras) gene, and are characterized by an 
enhanced Ras-PI3K-Akt cascade. We found a signifi-
cant inhibition of Akt phosphorylation by red wine, 
and fortification with resveratrol did not result in any 
significant difference compared to unfortified wine, 
indicating that chemicals present naturally in red wine 
are sufficient to significantly inhibit Akt. The only 
other study to show inhibition of Akt by wine was per-
formed by our lab (Barron et al. 2014). Resveratrol, at 
concentrations higher than those found naturally in 
wine, has been shown to inhibit Akt phosphorylation 
(100µM RSV) in human uterine cancer cells (Sexton et 
al. 2006) and radiation-induced Akt activation (2.5 or 
5µM RSV) in human prostate cancer cells (Rashid et 
al. 2011). Furthermore, combined treatment with res-
veratrol, quercetin and catechin (5µM each) inhibited 
Akt activity by 50% compared to control in breast can-
cer cells (Castillo-Pichardo et al. 2009). 
 Activated Ras also leads to downstream acti-
vation of ERK and enhanced cell proliferation. We 
found an inhibition of ERK phosphorylation/activation 
and similar to survival, proliferation and Akt effects, 
fortified wine did not have any statistically different/
enhanced effects compared to unfortified wine. The 
inhibition of ERK phosphorylation by red wine is in 
agreement with our previous study (Barron et al. 
2014). Resveratrol has been shown to inhibit ERK 
phosphorylation in transgenic adenocarcinoma mouse 
prostate (TRAMP) males (Harper et al. 2007) and 
50µM quercetin inhibited activation of ERK in human 
hepatoma cells (Granado-Serrano et al. 2006). Mice 
fed resveratrol (625mg/Kg) in their diet showed de-
creased ERK phosphorylation which contributed to an 
inhibition of proliferation, suppression of cancer devel-
opment and a reduction in the incidence of poorly dif-
ferentiated tumors (Harper et al. 2007), clearly indicat-
ing the potential for this polyphenol to have significant 
effects on this pathway.  Figure 7 summarizes the in-
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hibitory effects of red wine on Akt and ERK signaling 
cascades in cancer cells. These cascades are involved 
in cell survival and proliferation and future studies 
should examine if red wine has the same inhibitory 
effect on them in vivo. 
 Importantly, the results showed that fortified 
and unfortified red wine had no inhibitory effects on 
normal lung cell proliferation and did not alter the Akt 
or ERK signaling molecules in these cells, suggesting 
that wine selectively targets cancer cells and spares 
normal healthy cells. This finding suggests that moder-
ate consumption of red wine may exert beneficial 
health effects by inhibiting cancer cell proliferation 
and survival without affecting healthy cells. However, 
further studies should be performed in vivo to support 
this claim. 
 Although the data presented here do not sup-
port the use of resveratrol fortified wines for additional 
anticancer effects, it should be noted that further re-
search using in vivo animal cancer models should be 
performed. Resveratrol has been shown to have rela-
tively low oral bioavailability in human studies 
(Smoliga & Blanchard 2014) and is known to be me-
tabolized extensively in the body. Thus, increasing the 
concentration of resveratrol in wine may enhance its in 
vivo bioavailability and therefore enhance the health 
benefits. 
 In conclusion, the present study confirmed a 
significant inhibition of lung cancer cell survival and 
proliferation by red wine and an inhibition of Akt and 
ERK activation, key signaling molecules involved in 
cancer cell survival and proliferation. These findings 
were shown to be specific to cancer cells and were not 
seen in non-cancerous normal lung fibroblasts. To our 
knowledge this is the first study examining the effects 
of resveratrol-fortified wines at the cellular level. Al-
though more research using animal models of cancer 
and lung cancer xenograft studies are required, the data 
presented here suggest that caution should be taken 
when making claims of “additional health benefits” 
regarding phenolic-fortified wine beverages. 
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